In non-germinal center B-cell diffuse large B-cell lymphoma (GBC-DLBCL), characterized by high MYC protein expression and CDKN2A/B deletion, concomitant inhibition of ATR and the WEE1 kinase leads to DNA damage and G1 and intra S-phase cell cycle arrest, which pair with a strong cytotoxic response in in vivo DLBCL models [113]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.